Background

Competition is intensifying in the development of anti-aging therapeutics aimed at slowing or reversing biological age. While various biological age measurement tools, including epigenetic clocks, have been developed, most have been limited to correlation analyses in large-scale cohort epidemiological studies or preclinical stages. It had not been verified whether these tools could sensitively capture changes in biological age following drug administration in real-world clinical trial settings.

In particular, the recently highlighted proteomic aging clock is known to reflect the aging status of organs and the whole body by high-throughput analysis of thousands of circulating blood proteins. As it deals with proteins directly linked to disease biomarkers, expectations were high for its use as a tool to evaluate therapeutic response. However, it remained unknown whether proteomic aging clocks constructed independently by various research groups would produce consistent results from the same patient specimens, or whether they could reliably track subtle changes before and after drug administration. The lack of clinical validation has been cited as a major obstacle to proving the efficacy of the entire anti-aging drug pipeline.

Key Findings

The researchers applied six representative proteomic aging clocks simultaneously to clinical trial specimens from anti-aging intervention drug candidates. This is the first study to directly compare multiple proteomic aging clocks in a human randomized controlled clinical trial.

Analysis results revealed a significant discrepancy between the measurement tools rather than clearly proving the drug's biological rejuvenation effect. Even though the same patient plasma samples were analyzed, the baseline biological ages estimated by the six models were all different. While some models indicated a younger age at certain time points, others showed no change or even calculated an older age.

Measurement deviations stemmed from differences in the protein platforms used for model training and the design of the algorithms. The cross-consistency between models based on SomaScan and those based on Olink was low, and the correlation between organ-specific aging clocks and systemic aging clocks was also weak. In essence, the technical noise of the analytical tools themselves was greater than the actual biochemical perturbation caused by the drug on protein expression. Consequently, this trial demonstrated the urgent need for the standardization of the clock algorithms themselves before evaluating the anti-aging efficacy of drugs.

Implications and Outlook

This study forces a confrontation with the fact that proteomic aging clocks have not yet reached the level of a surrogate endpoint acceptable to regulatory agencies. For new drug approval, statistical validity—demonstrating that changes in specific biomarkers are directly linked to reduced mortality or improved function—is essential, but current proteomic clocks cannot even narrow the deviation between models.

Moving forward, the establishment of standardized reference protocols and reference protein panels must come first. Beyond presenting biological age in a single-score format, precision measurement techniques that evaluate individual metabolic pathways and immune responses separately are required. Although the initial clinical debut did not confirm dramatic anti-aging efficacy of the drug, it established a benchmark that aging biology must meet to mature into a science with clinical rigor.